These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

77 related items for PubMed ID: 8401619

  • 21. [Results of adjuvant intravesical Bacillus Calmette-Guérin therapy for grade 3 superficial bladder cancer].
    Yumura Y, Oogo Y, Takase K, Hamano A, Yamashita Y, Noguchi S, Satomi Y.
    Hinyokika Kiyo; 2004 Nov; 50(11):767-71. PubMed ID: 15628536
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. PDT combined with Intravesical BCG instillation would form an autovaccine for bladder cancer?
    Pan H, Ma X, Chen J, Jiang H.
    Med Hypotheses; 2009 Oct; 73(4):559-60. PubMed ID: 19556072
    [Abstract] [Full Text] [Related]

  • 25. Intravesical bacille Calmette-Guérin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression.
    Böhle A, Bock PR.
    Urology; 2004 Apr; 63(4):682-6; discussion 686-7. PubMed ID: 15072879
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. [Calmette-Guerin bacillus in the prophylaxis of superficial bladder tumors. Our experience and our doubts].
    Moyano Calvo JL, Sanz Sacristán J, Teba del Pino F, Fernández Arjona M, Peinado Ibarra F, Mélon Rey F, Herrero Torres L, Rabadán Ruiz M, Arellano Gañán R, Albacete Almodóvar P.
    Arch Esp Urol; 1995 Oct; 48(8):791-5. PubMed ID: 8526535
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. [Urinary leukocytes as a new prognostic marker of therapeutic response and of adverse effects associated with the maintenance treatment with endovesical BCG, for the prophylaxis of superficial bladder tumors].
    Saint F, Irani J, Salomon L, Legrand P, Abbou CC, Chopin D.
    Prog Urol; 2001 Dec; 11(6):1242-50. PubMed ID: 11859659
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Adverse drug reactions of intravesical bacillus Calmette-Guerin instillation and risk factors of the development of adverse drug reactions in superficial cancer and carcinoma in situ of the bladder.
    Koga H, Kuroda M, Kudo S, Yamaguchi A, Usami M, Suzuki T, Naito S.
    Int J Urol; 2005 Feb; 12(2):145-51. PubMed ID: 15733108
    [Abstract] [Full Text] [Related]

  • 35. Intravesical instillation of bacille Calmette-Guérin for superficial bladder cancer: cost-effectiveness analysis.
    Uchida A, Yonou H, Hayashi E, Iha K, Oda M, Miyazato M, Oshiro Y, Hokama S, Sugaya K, Ogawa Y.
    Urology; 2007 Feb; 69(2):275-9. PubMed ID: 17320663
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Intravesical bacillus Calmette-Guérin therapy for T1 superficial bladder cancer.
    Demkow T, Alter A, Wiechno P.
    Urol Int; 2008 Feb; 80(1):74-9. PubMed ID: 18204238
    [Abstract] [Full Text] [Related]

  • 40. Intravesical instillations with bacillus calmette-guérin for the treatment of carcinoma in situ involving prostatic ducts.
    Palou Redorta J, Schatteman P, Huguet Pérez J, Segarra Tomás J, Rosales Bordes A, Algaba F, Villavicencio Mavrich H.
    Eur Urol; 2006 May; 49(5):834-8; discussion 838. PubMed ID: 16426729
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 4.